In vivo xenograft responses to vincristine, dexamethasone, and methotrexate
. | Median EFS, d . | . | . | . | GDF value, d . | . | . | . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Xenograft . | Control . | VCR . | DEX . | MTX . | VCR . | DEX . | MTX . | Patient status . | |||||
| 2 | 18.6 | 46.0 | 50.4 | ND | 27.4 | 31.8 | ND | Deceased | |||||
| 3 | 5.2 | 57.2 | 68.6 | 57.4 | 52.0 | 63.4 | 52.2 | Alive | |||||
| 4 | 3.2 | 34.5 | ND | 56.0 | 31.3 | ND | 52.8 | Deceased | |||||
| 7 | 8.4 | 17.6 | 39.0 | 56.0 | 9.2 | 30.6 | 47.6 | Deceased | |||||
| 8 | 10.9 | 35.3 | 29.6 | 14.3 | 24.4 | 18.7 | 3.4 | Deceased | |||||
| 10 | 9.2 | 44.0 | ND | ND | 34.8 | ND | ND | Alive | |||||
| 11 | 18.8 | 77.3 | 79.0 | 62.0 | 58.5 | 60.2 | 43.2 | Alive | |||||
| 16 | 11.8 | 42.0 | 64.6 | 21.1 | 30.2 | 52.8 | 9.3 | Alive | |||||
| 17 | 6.2 | 56.1 | 38.0 | 58.7 | 49.9 | 31.8 | 52.5 | Alive | |||||
| 19 | 6.7 | 40.6 | 14.8 | 60.2 | 33.9 | 8.1 | 53.5 | Deceased | |||||
. | Median EFS, d . | . | . | . | GDF value, d . | . | . | . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Xenograft . | Control . | VCR . | DEX . | MTX . | VCR . | DEX . | MTX . | Patient status . | |||||
| 2 | 18.6 | 46.0 | 50.4 | ND | 27.4 | 31.8 | ND | Deceased | |||||
| 3 | 5.2 | 57.2 | 68.6 | 57.4 | 52.0 | 63.4 | 52.2 | Alive | |||||
| 4 | 3.2 | 34.5 | ND | 56.0 | 31.3 | ND | 52.8 | Deceased | |||||
| 7 | 8.4 | 17.6 | 39.0 | 56.0 | 9.2 | 30.6 | 47.6 | Deceased | |||||
| 8 | 10.9 | 35.3 | 29.6 | 14.3 | 24.4 | 18.7 | 3.4 | Deceased | |||||
| 10 | 9.2 | 44.0 | ND | ND | 34.8 | ND | ND | Alive | |||||
| 11 | 18.8 | 77.3 | 79.0 | 62.0 | 58.5 | 60.2 | 43.2 | Alive | |||||
| 16 | 11.8 | 42.0 | 64.6 | 21.1 | 30.2 | 52.8 | 9.3 | Alive | |||||
| 17 | 6.2 | 56.1 | 38.0 | 58.7 | 49.9 | 31.8 | 52.5 | Alive | |||||
| 19 | 6.7 | 40.6 | 14.8 | 60.2 | 33.9 | 8.1 | 53.5 | Deceased | |||||
EFS indicates event-free survival; GDF, growth delay factor; VCR, vincristine; DEX, dexamethasone; MTX, methotrexate; ND, not done.